user avatar
Circulation
@CircAHA
RT/follows do not imply endorsement.
Boston, MA
Joined February 2012
Posts
  • user avatar
  • user avatar
    #Perspective: How should we sequence the treatments for HFrEF? A redefinition of evidence-based medicine ow.ly/QWjd50DN73V #AHAJournals @UoGHeartFailure
  • user avatar
    Read the New Universal Definition of MI in Circulation ow.ly/Rqbz30lxNrT
  • user avatar
    Does my patient have HFpEF? How can I make an evidence based diagnosis? Learn More: ow.ly/sx1h30lzJlO @yreddyhf
  • user avatar
    2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation #AHAJournals
  • user avatar
    #WhitePaper: Value of Hemodynamic Monitoring in Patients with Cardiogenic Shock Undergoing Mechanical Circulatory Support ow.ly/jmCA50za8HP #AHAJournals
  • user avatar
    #CircECG: A 35 yo woman is admitted for septic shock with group A strep bacteremia and a hand abscess from IVDU. TEE showed a TV vegetation with mild-mod regurgitation. Lung CT showed septic emboli. What is the sign seen on ECG? ow.ly/IvzH50AhW0g #AHAJournals
  • user avatar
    Just Published: 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ow.ly/Y8Y350Ccude #AHAJournals @AHAScience
  • user avatar
    Cardiorenal syndrome 💔: Recent scientific work identifies fibrosis as a common pathophysiologic feature for this vicious and interrelated cycle. Perhaps this can lead to novel therapeutic targets. Learn more: ow.ly/9DMJ30lBFCr
  • user avatar
    #Editorial: ECMO for Cardiogenic Shock: When to open the Parachute? #AHAJournals ahajrnls.org/3lrs3vM
  • user avatar
    The multidisciplinary Shock Team approach for the treatment of refractory cardiogenic shock decreased in-hospital and 30-day all-cause mortality ow.ly/euZU50uQZNw | #AHAJournals @JoeTonnaMD @StavrosDrakos @Joseph_Taleb @UofUHealth
  • user avatar
    Just Published Online: #InDepthReview: Science and #COVID19: Implications for the CV System #AHACOVID19 #AHAJournals @AHAScience ow.ly/1rag50zfkwW
  • user avatar
    EMBRACE- HF: In patients with HF and CardioMEMS, empagliflozin produced rapid reductions in PA pressures that were amplified over time and appeared to be independent of loop diuretic management ow.ly/I0A650Ey63u #AHAJournals @MkosiborodMD @MichaelNassifMD
  • user avatar
    IAPB-SHOCK II Trial: 6 year results confirm no longer term benefit of #IABP in STEMI w/cardiogenic shock; high (~66%) mortality rate #CircAHA18 #AHA18 ow.ly/Hwye30myK19